← Leaderboards
Joseph M Tuscano
Va Northern California Health Care Sys
$91,254
Attributed
$91,254
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $0 · FY2013–25$1$1$1$0$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$91,254 · 2
VA$0 · 2
By mechanism
K08$84,780 · 1
M01$6,474 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Va Northern California Health Care Sys
Same institution · by research overlap
Others in their field
Top investigators on “Non-Hodgkin&Apos”
- Trudy M Forte · University Of Calif-Lawrenc Berkeley Lab$109,354
Research focus
Non-Hodgkin&AposReceptorChemotherapyProductionToxic EffectUnited StatesIn VivoClinical TrialsMediatingNon-Small-Cell Lung CarcinomaS LymphomaSurvival RateCancer TherapyTumorCytotoxicityLigandsDoseImmuneMalignant Neoplasm Of LungMalignant NeoplasmsCancer Cell LineClinical ResearchAnimal ModelBase
Grant awards (12)
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2025 · VA · contact PI
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2024 · VA · contact PI
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2023 · VA · contact PI
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2022 · VA · contact PI
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2021 · VA · contact PI
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies$0
I01 · FY2020 · VA · contact PI
CD22-targeted Therapeutics for the Treatment of Lung Cancer$0
I01 · FY2016 · VA · contact PI
CD22-targeted Therapeutics for the Treatment of Lung Cancer$0
I01 · FY2015 · VA · contact PI
CD22-targeted Therapeutics for the Treatment of Lung Cancer$0
I01 · FY2014 · VA · contact PI
CD22-targeted Therapeutics for the Treatment of Lung Cancer$0
I01 · FY2013 · VA · contact PI
PHASE II TRIAL OF BEVACIZUMAB VS BEVACIZUMAB, THALIDOMIDE FOR RELAPSED/REFRACTOR$6,474
M01 · FY2004 · RR
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM$84,780
K08 · FY2000 · CA